Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-07-22
2010-12-07
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S187000
Reexamination Certificate
active
07846946
ABSTRACT:
Disclosed are novel compounds of the formulaor a pharmaceutically acceptable salt thereof, wherein:M1and M3are CH or N;M2is CH, CF or N;Y is —C(═O)—, —C(═S)—, —(CH2)q—, —C(═NOR7)— or —SO1-2—;Z is a bond or optionally substituted alkylene or alkenylene;R1is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula:where ring A is a heteroaryl ring;R2is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl;R3is H, —C(O)NH2, or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted;and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.
REFERENCES:
patent: 4983597 (1991-01-01), Yang et al.
patent: 5306817 (1994-04-01), Thiruvengadam et al.
patent: 5561227 (1996-10-01), Thiruvengadam et al.
patent: 5618707 (1997-04-01), Homann et al.
patent: 5624920 (1997-04-01), McKittrick et al.
patent: 5627176 (1997-05-01), Kirkup et al.
patent: 5631365 (1997-05-01), Rosenblum et al.
patent: 5633246 (1997-05-01), McKittrick et al.
patent: 5656624 (1997-08-01), Vaccaro et al.
patent: 5661145 (1997-08-01), Davis
patent: 5688785 (1997-11-01), Vaccaro
patent: 5688787 (1997-11-01), Burnett et al.
patent: 5688990 (1997-11-01), Shankar
patent: 5698548 (1997-12-01), Dugar et al.
patent: 5728827 (1998-03-01), Thiruvengadam et al.
patent: 5739321 (1998-04-01), Wu et al.
patent: 5744467 (1998-04-01), McKittrick et al.
patent: 5756470 (1998-05-01), Yumibe et al.
patent: 5767115 (1998-06-01), Rosenblum et al.
patent: 5846966 (1998-12-01), Rosenblum et al.
patent: 5856473 (1999-01-01), Shankar
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 5886171 (1999-03-01), Wu et al.
patent: 5919672 (1999-07-01), Homann et al.
patent: 6093812 (2000-07-01), Thiruvengadam et al.
patent: 6096883 (2000-08-01), Wu et al.
patent: 6133001 (2000-10-01), Homann et al.
patent: 6207822 (2001-03-01), Thiruvengadam et al.
patent: RE37721 (2002-05-01), Rosenblum et al.
patent: 6627757 (2003-09-01), Fu et al.
patent: 6632933 (2003-10-01), Altmann et al.
patent: 6720328 (2004-04-01), Aslanian et al.
patent: 6720378 (2004-04-01), Maruyama et al.
patent: 6849621 (2005-02-01), Rosenblum et al.
patent: 2002/0039774 (2002-04-01), Kramer et al.
patent: 2002/0128252 (2002-09-01), Glombik et al.
patent: 2002/0128253 (2002-09-01), Glombik et al.
patent: 2002/0137689 (2002-09-01), Glombik et al.
patent: 2003/0105028 (2003-06-01), Ghosal et al.
patent: 2004/0019099 (2004-01-01), Aslanian et al.
patent: 2004/0048843 (2004-03-01), Ting et al.
patent: 2004/0097483 (2004-05-01), Zeng et al.
patent: 2004/0180860 (2004-09-01), Burnett et al.
patent: 2004/0180861 (2004-09-01), Burnett et al.
patent: 2004/0198700 (2004-10-01), Burnett et al.
patent: 2004/0198743 (2004-10-01), Hey et al.
patent: 2004/0224953 (2004-11-01), Cowart et al.
patent: WO 98/06394 (1998-02-01), None
patent: WO 99/65867 (1999-12-01), None
patent: WO 01/58891 (2001-08-01), None
patent: WO 02/32893 (2002-04-01), None
patent: WO 02/066464 (2002-08-01), None
patent: WO 02/072570 (2002-09-01), None
patent: WO 03/088967 (2003-10-01), None
patent: WO 03/103669 (2003-12-01), None
patent: WO 04/000831 (2003-12-01), None
patent: WO 2004/005247 (2004-01-01), None
patent: WO 2004/014947 (2004-02-01), None
patent: WO 2004/087655 (2004-10-01), None
patent: WO 2004/089373 (2004-10-01), None
patent: WO 2004/101546 (2004-11-01), None
patent: WO 2004/000803 (2004-12-01), None
patent: WO 2004/000804 (2004-12-01), None
patent: WO 2004/000805 (2004-12-01), None
patent: WO 2005/000353 (2005-01-01), None
patent: WO 2005/002897 (2005-01-01), None
patent: WO 2005/009955 (2005-02-01), None
patent: WO 2005/021495 (2005-03-01), None
patent: WO 2005/021497 (2005-03-01), None
patent: WO 2005/023305 (2005-03-01), None
patent: WO 2005/030225 (2005-04-01), None
patent: WO 2005/033100 (2005-04-01), None
patent: WO 2005/042692 (2005-05-01), None
patent: WO 2005/044256 (2005-05-01), None
patent: WO 2005/046662 (2005-05-01), None
patent: WO 2005/047248 (2005-05-01), None
patent: WO 2005/061451 (2005-07-01), None
patent: WO 2005/061452 (2005-07-01), None
patent: WO 2005/062824 (2005-07-01), None
Alzheimer's Treatment. Retrieved online Oct. 2, 2010, URL: http://www.nlm.nih.gov/medlineplus/attentiondeficithyperactivitydisorder.html.
Attention deficit hyperactivity Disorder. Retrieved online Oct. 2, 2010, URL: http://www.nlm.nih.gov/medlineplus/attentiondeficithyperactivitydisorder.html.
Anderson et al.,The Practice of Medicinal Chemistry, Academic Press, New York, 739-754,(1996).
Berge et al.,Journal of Pharmaceutical Sciences, 66(1) 1-19 (1977).
Bingham et al., Over one hundred solvates of sulfathiazole,Chem, Commun., 603-604 (2001).
Caira et al., Preparation and Crystal Characterization of a Polymorph, a Monohydrate, and an Ethyl Acetate Solvate of the Antifungal Fluconazole,J. Pharmaceutical Sci., 93(3), 601-611 (2004).
Gould, Salt selection for basic drugs,International J. of Pharmaceutics33 201-217 (1986).
Greene et al., Protective Groups in organic Synthesis, Wiley, New York (1991).
Grundy et al., Definition of Metabolic Syndrome, Circulation, 109:433-438 (2004).
Leurs et al., The Histamine H3Receptor: From Gene Cloning to H3Receptor Drugs,Nature Reviews, Drug Discovery, 4:107(2005).
McLeod et al., Pharmacological Characterization of the Novel Histamine H3-Receptor AntagonistsN-(3,5-Dichlorophenyl)-N′-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687),The Journal of Pharmacology and Experimental Therapeutics, 305:3, 1037-1044 (2003).
Ram et al., Potential hypolipidemic agents: Part V—Synthesis and biological activity of new ethyl 4-(2-oxoazetidin-4-yl)phenoxyalkanoates,Indian J. Chem., 29:B, 1134-1137 (1990).
Rizzo et al., Pharmacological characterization of histamine H3receptors in isolated guinea pig pulmonary artery and ileum,Eur. J. Pharmacol., vol. 294, 329-335 (1995).
Roche, Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, (1987).
Stahl, et al,Handbook of Pharmaceutical Salts. Properties, Selection and Use, (2002).
van Tonder et al., Preparation and Physicochemical Characterization of 5 Niclosamide Solvates and 1 Hemisolvate,AAPS PharmSciTech., 5(1), article 12 (2004).
Witkin, Selective histamine H3receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system,Pharmacology and Therapeutics, 103, 1-20 (2004).
Written Opinion of the International Search Authority—6 Pages.
Aslanian Robert G.
Berlin Michael Y.
Boyce Christopher W.
Chao Jianhua
de Lera Ruiz Manuel
Devlin Gerard M.
Saeed Kamal A
Schering Plough Corporation
Shterengarts Samantha L
Thies J. Eric
LandOfFree
Heteroatom-linked substituted piperidines and derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroatom-linked substituted piperidines and derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroatom-linked substituted piperidines and derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4151015